58,411 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 58,411 shares of the medical research company's stock, valued at approximately $11,478,000.

Several other hedge funds have also recently added to or reduced their stakes in IQV. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter valued at approximately $1,616,000. Hickory Asset Management Inc. purchased a new position in IQVIA during the fourth quarter valued at approximately $941,000. Graphene Investments SAS lifted its position in IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after buying an additional 2,700 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares during the period. Finally, Compound Global Advisors LLC acquired a new position in shares of IQVIA in the fourth quarter worth $334,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Down 0.6%

Shares of IQV stock traded down $0.86 during trading hours on Friday, reaching $140.16. The company had a trading volume of 2,874,682 shares, compared to its average volume of 1,578,625. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a 50 day moving average of $150.79 and a 200 day moving average of $180.93. The firm has a market cap of $24.25 billion, a price-to-earnings ratio of 18.69, a P/E/G ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. During the same quarter in the previous year, the company earned $2.54 earnings per share. The business's revenue for the quarter was up 2.5% on a year-over-year basis. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

IQV has been the topic of a number of recent research reports. Morgan Stanley boosted their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Redburn Partners set a $188.00 price target on IQVIA in a research note on Friday, May 23rd. Barclays cut their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Finally, HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and lowered their price target for the company from $260.00 to $160.00 in a report on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $226.32.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.